Skip to main content

Table 1 Demographic and transplant characteristics of the study population

From: The effect of zoledronic acid on hip geometry in renal transplant recipients: a double-blind placebo-controlled randomized study

Parameters

Intervention

N (%)

Mean ± SD

Placebo

N (%)

Mean ± SD

P value

Female

5 (27.8%)

4 (26.7%)

0.627

Male

13 (72.2%)

11 (73.3%)

Premenopausal women

2 (11.1%)

2 (13.33%)

0.643

Age (y)

51.22 c 13.53

45.60 ± 15.50

0.275

Female age(y)

48.00 ± 10.24

34.75 ± 14.93

0.157

Male age(y)

52.46 ± 14.785

49.55 ± 14.32

0.630

Time on dialysis(months)a

24.00 (22.00)

22.00 (12.5)

0.400

End stage renal disease etiology N (%)

 

0.828

 Hypertensive disease

8 (44.4)

9 (60)

 Diabetic nephropathy

4 (22.2)

3 (20)

 Glomerulonephritis/vasculitis

1 (5.6)

0 (0)

 Cystic/hereditary/congenital diseases

1 (5.6)

0 (0)

 Other

4 (22.2)

3 (20)

Estimated glomerular filtration rate before transplant (ml/min)

11.265 ± 4.891

10.716 ± 3.992

0.742

Physical activity (total METs)a

321.75(618.75)

198 (643.5)

0.919

  1. METs Metabolic equivalents
  2. aNon-parametric values are reported as median (IQR)